Indian Biosimilars: Going Global
Deloitte predicts that the global market for biosimilars will reach between USD 25 and 35 billion by 2020, driven by some key global biologic drugs facing loss of exclusivity in…
Address: Eli Lilly and Company (India) pvt. Ltd., Plot# 92, Sector 32, Institutional Area, Gurgaon-122001, HARYANA, INDIA ,India
Tel: 91-124-4753000, 01
Web: https://www.lillyindia.co.in/
Eli Lilly and Company established its India operations in 1993 as a Joint venture with Ranbaxy Laboratories’ Limited. After the divestiture in 2001 it was Christened Eli Lilly and Company (India) Pvt. Ltd, and is today one of the most admired companies in terms of its focus on scientific selling, unique bouquet of products and services, working environment and focus on Ethics and Compliance Lilly India provides innovative answers to the needs of the people suffering from Diabetes, Cancer, Sepsis, Osteoporosis, Cardiovascular disorders and Growth hormone deficiency.
Major Achievements of Eli Lilly and Company (India) Pvt. Ltd.
In top 25 “Great Places to Work For in India” in 2003 and 2004 in a survey conducted by ‘Great Places to Work’ Institute
In top 25 in 2003 “Best Employers in India” in a survey conducted by Hewitt Associates.
2nd Best company to work for under ‘Biotech & Pharmaceutical’ category in 2008 in a survey conducted by Great Places to Work Institute USA’.
In top 10 “Best Companies to Work for in India’ in Business Today-Mercer-TNS survey 2008. Ranked 9th overall, achieving the unique distinction of being the only Pharmaceutical Company in this list.
We strive to touch the lives of our customers by actively listening and responding to their needs with breakthrough products and medical expertise that is critical to their understanding and treatment of diseases.
Deloitte predicts that the global market for biosimilars will reach between USD 25 and 35 billion by 2020, driven by some key global biologic drugs facing loss of exclusivity in…
Alexandre Williams, founder and managing director of Athena, an international company with an Indian manufacturing basis specialized in life cycle products, provides insights into some key trends shaping India’s pharmaceutical…
As the founder and chairman of Alves Group, a key Indian player in medical devices with an extensive portfolio, Randolph Alves shares the challenges India needs to overcome to remain…
Dharmesh Shah, managing director of BDR Pharmaceuticals, a company with a strong expertise in oncology, intensive care, and other therapeutic areas, provides us with an insightful overview of the main…
For multinational companies, despite ‘pharmerging markets’ not holding the hype and allure they once did, India still stands as a land of opportunity for a variety of reasons. Novartis India…
Umang Vohra, managing director and global CEO of Indian pharma giant Cipla, discusses the company’s ambition to grow in both the domestic and emerging markets as well as the opportunities…
Nikhil Masurkar, executive director of Entod Pharmaceuticals, talks about the company’s ambition to invest in stem cell research and become market leaders in the field of ophthalmology in ten years’…
Manni Kantipudi, CEO of GVK BIO, talks about the evolution of the company, which he took from USD 20 million to its current USD 120 million, its future, its strategic…
R.S. Subramanian, country manager and Sandeep Juneja, vice president – Sales and Marketing, DHL Express India, explain why the world’s leading express logistics company is a trusted and accountable service…
A passionate advocate for Indian patients, Sanjiv Navangul, managing director of Janssen India, discusses the company’s public health work in the field of tuberculosis (TB) and multi-drug resistant TB (MDR-TB)…
A strong advocate for quality, Dilip Surana, chairman and managing director of Micro Labs, explains how the company’s strong focus on the quality of its products and move to specialty…
Amit Mookim, IQVIA’s general manager for South Asia, discusses the major trends impacting the Indian pharmaceutical market and how Indian companies are rethinking their commercial strategies and becoming more specialized…
See our Cookie Privacy Policy Here
